COPENHAGEN (Reuters) – Novo Nordisk, the maker of weight-loss drug Wegovy, has bought a site in Denmark’s third largest city Odense and begun preparatory excavation works for a potential new production plant, it said on Tuesday,
Novo last year became Europe’s most valuable company due to the success of its weight-loss treatment Wegovy and diabetes drug Ozempic.
The company has spent billions to boost production – mostly in its native Denmark and in the United States – as it has struggled to meet huge demand.
Odense will be a new site for the drug maker.
“With the political processes and approvals in place, we are pleased to announce that Novo Nordisk is now the owner of the site in Tietgenbyen in Odense,” the company said in an emailed statement.
Novo expects to make a final investment decision at the end of the year, it said.
(Reporting by Jacob Gronholt-Pedersen; Editing by Kirsten Donovan)
Comments